May 2007

Alzheimer's Disease and AMD May Share a Common Link

CONNI BERGMANN KOURY, EDITOR-IN-CHIEF

Real-World Dosing Strategies for Ranibizumab

Landmark trials have changed the way neovascular AMD is managed; however, the administration schedule used in the trials places a burden on patients,subspecialists, and the entities that pay for health care.

PHILIP J. ROSENFELD, MD, PhD

The Neovascular AMD Treatment Landscape

The true potential may be in combination therapy.

PETER K. KAISER, MD

Triple Therapy for CNV Due to AMD: An Update

Combination therapy strategies are common elsewhere in medicine, especially in oncology, the discipline from which anti-VEGF therapy originated.

INDRE OFFERMANN, MD, AND ALBERT J. AUGUSTIN, MD

Omega-3s and Angiogenesis

The AREDS study found an association between greater fish intake and reduced risk of AMD progression. AREDS 2 hopes to further qualify the relationship between dietary supplements and AMD.

EMILY Y. CHEW, MD

Zinc Found to Be a Link in AMD

ERIK van KUIJK, MD, PhD

Sirolimus and mTOR Inhibition in Ocular Disease: An Update

Due to the broad immunomodulatory and antihypoxic-response activities of sirolimus, the drug has the potential to fill a critical unmet need: The prevention of CNV in AMD.

MARK S. BLUMENKRANZ, MD

Topical Multitarget Agent Readying for Phase 2 Trial

Efficacy studies will determine how on target TG100801 is in humans.

CONNI BERGMANN KOURY, EDITOR-IN-CHIEF

Emerging Treatments for Diabetic Retinopathy

A number of studies show future treatments can control DR and minimize progression.

LEAH D. FARR, ASSOCIATE EDITOR

Current Clinical Management of ROP

ROP will continue to be a threat for vision in this world of micropreemies.

AUDINA M. BERROCAL, MD

AWARE Study to Clarify Safety of Anti-VEGF Agents

The AWARE group hopes this study will serve as a model for safety analyses for drugs developed in the retina arena and beyond.

CONNI BERGMANN KOURY, EDITOR-IN-CHIEF

The Rationale for Selective VEGF Inhibition

It is important to consider the systemic safety of these ocular treatments in the AMD patient population, especially over the long term.

THOMAS R. FRIBERG, MD

Update from 2007 ARVO

ASSOCIATION FOR RESEARCH AND VISION IN OPHTHALMOLOGY 2007 ANNUAL MEETING

The 2007 meeting was held from May 6 to May 10 in Fort Lauderdale, Fla.

All About PrONTO: Study Yielded Good Results in AMD With Treatment Guided by OCT

Jointly sponsored by The Dulaney Foundation and Retina Today Release Date: May 2007. Expiration Date: June 30, 2008. This continuing medical education activity is supported by an educational grant from Genentech.

GEETA A. LALWANI, MD

5 Questions with Jay Duker, MD

Jay Duker, MD, is the Chairman of the Ophthalmology Department at Tufts University School of Medicine and Tufts-New England Medical Center.

Jay Duker, MD